Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q3 EPS of ($0.47), $0.07 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $4.89 million versus the consensus estimate of $3.64 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.